All Releases
 |
Dynavax Selects Clinical Candidate in Universal Flu Vaccine Program
Feb 25, 2010
|
11.1 KB |
|
| |
BERKELEY, CA, Feb 25, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has selected a clinical vaccine candidate for its novel Universal Flu program, completed key preclinical studies, and is reviewing clinical plans with the FDA in anticipation of initiating a Phase I study by mid...
|
|
Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program
Feb 18, 2010
|
9.3 KB |
|
| |
BERKELEY, CA, Feb 18, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the selection of a candidate for clinical development in its endosomal Toll-like Receptor (TLR) inhibitor collaboration with GlaxoSmithKline. The selected molecule DV1179, a bifunctional TLR inhibitor, has moved into ad...
|
|
Dynavax Receives Canadian Approval to Conduct Phase 3 Trials of HEPLISAV(TM)
Feb 16, 2010
|
9.9 KB |
|
| |
BERKELEY, CA, Feb 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced that Health Canada, the Canadian equivalent of the U.S. Food and Drug Administration, has approved the initiation of the Company's next Phase 3 trials in Canada. Initiation of the Canadian studies is expected to facilitate en...
|
|
Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)
Feb 8, 2010
|
10.0 KB |
|
| |
BERKELEY, CA, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV(TM), the Company's investigational adult hepatitis B va...
|
|
Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection
Jan 26, 2010
|
10.6 KB |
|
| |
BERKELEY, CA, Jan 26, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of ac...
|
|
Dynavax Expands Commercial and Clinical Leadership
Jan 12, 2010
|
10.0 KB |
|
| |
BERKELEY, CA, Jan 12, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the addition of two new senior executives to direct key commercial and clinical activities prior to the launch of HEPLISAV(TM), an investigational adult hepatitis B vaccine.
Brant Biehn, after more than 20 years wit...
|
|
Dynavax Completes Symphony Dynamo Acquisition
Jan 4, 2010
|
10.1 KB |
|
| |
BERKELEY, CA, Jan 04, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that stockholders approved the acquisition of Symphony Dynamo, Inc. (SDI), including approximately $20 million in cash and all rights to Dynavax's hepatitis C and cancer therapy programs.
Dynavax expects the proceed...
|
|
Dynavax's European Manufacturing Facility Approved for Commercial Production of HEPLISAV Hepatitis B Surface Antigen
Dec 9, 2009
|
9.6 KB |
|
| |
BERKELEY, CA and DUSSELDORF, GERMANY, Dec 09, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that its GMP manufacturing facility in Duesseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV(TM), the Company's investig...
|
|
Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy
Nov 19, 2009
|
8.2 KB |
|
| |
BERKELEY, CA, Nov 19, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile of patients in the first cohort met pre-specified crite...
|
|
Dynavax to Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash
Nov 10, 2009
|
12.0 KB |
|
| |
BERKELEY, CA, Nov 10, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has exercised its option to purchase all of the equity of Symphony Dynamo, Inc. (SDI). As a result, Dynavax will acquire approximately $20 million in cash and regain all rights to its hepatitis C and cancer ther...
|
|
Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors
Nov 5, 2009
|
7.6 KB |
|
| |
BERKELEY, Calif., Nov 05, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that
Francis R. Cano, Ph.D. has been appointed to Dynavax's Board of
Directors effective November 3, 2009.
"A recognized scientific leader in vaccines and infectious diseases,
Francis brings unique expertise and ...
|
|
Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients
Oct 29, 2009
|
13.1 KB |
|
| |
BERKELEY, Calif., Oct 29, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the
first clinical data for HEPLISAVTM investigational hepatitis
B vaccine in chronic kidney disease patients. These data will be
presented in a poster session on Saturday, October 31, 2009 at the 47th
An...
|
|
Dynavax Announces Third Quarter 2009 Financial Results
Oct 22, 2009
|
22.1 KB |
|
| |
BERKELEY, Calif., Oct 22, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported financial
results for the third quarter and nine months ended September 30, 2009.
Dynavax reported $46.4 million in cash, cash equivalents, marketable
securities and investments held by Symphony Dynamo, Inc. (SDI),
...
|
|
Dynavax to Report Third Quarter 2009 Financial Results after Market Closes on October 22, 2009
Oct 21, 2009
|
7.6 KB |
|
| |
BERKELEY, Calif., Oct 21, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it
plans to report third quarter 2009 financial results after the market
closes on Thursday, October 22, 2009.
The Company also plans to host a webcast of a conference call on
Thursday, October 22, 2009 at ...
|
|
Dynavax to Present at the Oppenheimer Healthcare Conference
Oct 20, 2009
|
7.6 KB |
|
| |
BERKELEY, Calif., Oct 20, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it
plans to present at the Oppenheimer 20th Annual Healthcare
Conference on Tuesday, November 3, 2009 at 10:15 am EST (7:15 am PST) at
the Waldorf Astoria Hotel in New York.
Dino Dina, M.D., President and Ch...
|
|
Dynavax Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAVTM Hepatitis B Vaccine
Sep 29, 2009
|
10.7 KB |
|
| |
BERKELEY, Calif., Sep 29, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the
initiation of a Phase 3 registration trial for HEPLISAVTM
hepatitis B vaccine in individuals with chronic kidney disease. A second
registration trial, a Phase 3 lot-to-lot consistency trial, is expected
...
|
|
Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference
Sep 22, 2009
|
7.8 KB |
|
| |
BERKELEY, Calif., Sep 22, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that an
abstract with chronic kidney disease patient data for HEPLISAVTM,
an investigational adult hepatitis B vaccine, will be presented at the 47th
Annual Meeting of the Infectious Disease Society of America (ID...
|
|
Dynavax Reports FDA Removes Clinical Hold on HEPLISAVTM Phase 3 Hepatitis B Vaccine
Sep 10, 2009
|
10.0 KB |
|
| |
BERKELEY, Calif., Sep 10, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that the
U.S. Food and Drug Administration (FDA) has removed the clinical hold
for the HEPLISAVTM Investigational New Drug (IND) application
in individuals with chronic kidney disease. HEPLISAV is a Phase 3
...
|
|
Dynavax Announces European Development Strategy for HEPLISAV Hepatitis B Vaccine
Aug 12, 2009
|
9.2 KB |
|
| |
BERKELEY, Calif., Aug 12, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that it
has met with the European Medicines Evaluation Agency (EMEA) to discuss
its plans for continued clinical development of HEPLISAVTM
Phase 3 investigational adult hepatitis B vaccine in Europe.
In a Scienti...
|
|
Dynavax Announces Retirement of Chief Financial Officer
Aug 7, 2009
|
7.5 KB |
|
| |
BERKELEY, Calif., Aug 07, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a clinical-stage
biopharmaceutical company that discovers and develops novel products to
prevent and treat infectious diseases, today announced that Deborah A.
Smeltzer, Vice President, Operations and Chief Financial Officer, i...
|
|
|